Multi-Functional Cell Therapies Summit
When:
Tuesday, May 04, 2021 9:00a -
Thursday, May 06, 2021 5:00p
Tuesday, May 04, 2021 9:00a -
Thursday, May 06, 2021 5:00p
Where:
Online
United States
United States, Online
Admission:
$3297.0
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/727216-2?pid=5248
The future of cell therapies is multi-faceted. At the Multi-Functional Cell Therapies Summit, we gather pioneers at the forefront of development to discuss the next generation of cell therapies, which boast safer, more efficacious targeting profiles.
Join Global Innovators to:
- Investigate and overcome relapse and resistance: leverage functional analysis, novel combination strategy, and dual-CAR approaches with Kite: A Gilead Company, In8bio and Leucid Bio Ltd.
- Harness the power of multiple cell types: from NK to gamma delta to TILs, using combination and hybrid modalities developed by Eureka Inc., NKarta Therapeutics and Iovance Biotherapeutics
- Implement logic and develop 'decision-making' cells: create robust, controllable activation in vivo with University of Pennsylvania and Ludwig Institute for Cancer Research Lausanne
URLs:
Tickets: https://go.evvnt.com/727216-0?pid=5248
Brochure: https://go.evvnt.com/727216-3?pid=5248
Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 2697.0,
Drug Developer Pricing - Conference + 1 Workshop: USD 2348.0,
Drug Developer Pricing - Conference Only: USD 1999.0,
Academic Pricing - Conference + 2 Workshops: USD 2397.0,
Academic Pricing - Conference + 1 Workshop: USD 2098.0,
Academic Pricing - Conference Only: USD 1799.0,
Standard Pricing - Conference + 2 Workshops: USD 3297.0,
Standard Pricing - Conference + 1 Workshop: USD 2898.0,
Standard Pricing - Conference Only: USD 2499.0
Speakers: Eduardo Laborda, Calibr at Scripps Research, Jordan Jarjour, bluebird bio, Saul Priceman, City of Hope, Shon Green, Umoja Therapeutics, Sicco Popma, IO Bio Science, Travis Young, Calibr at Scripps Research, Melita Irving, Ludwig Institute for Cancer Research Lausanne, Micah Benson, KSQ Therapeutics, Nadia Agopyan, Marker Therapeutics, Natalia Venetz, Molecular Partners, Peggy Sotiropoulou, Celyad Oncology, Richard Boyd, Cartherics Ltd., Juan Vera, Marker Therapeutics, Lawrence Lamb, In8Bbio, Linnette Zhou, CARsgen Therapeutics, Madan Jagasia, Iovance Biotherapeutics Inc., Marc Van Dijk, AgenTus Therapeutics, Marco Ruella, University of Pennsylvania, Francesco Marincola, Refuge Biotech, Hanspeter Gerber, 3T Biosciences, Jakob Dupont, Atara Biotherapeutics, Jan Ter Meulen, Obsidian Therapeutics, John Maher, Leucid Bio Ltd., John Rossi, Kite: A Gilead Company, Alan Trounson, Cartherics Ltd., Cheng Liu, Eureka Inc., Christopher Haqq, Elicio Therapeutics, Daniel Abate Daga, Moffitt Cancer Center
